Risk-guided cardioprotection in cardio-oncology

This publication has 64 references indexed in Scilit:

• An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program
  JAMA, 2025
• Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines
  JAMA Network Open, 2025
• Clinical Applications of Strain Echocardiography: A Clinical Consensus Statement From the American Society of Echocardiography Developed in Collaboration With the European Association of Cardiovascular Imaging of the European Society of Cardiology
  Journal of the American Society of Echocardiography, 2025
• Artificial Intelligence for Identification of Patients with Increased Risk of Severe Cancer Therapy-Related Cardiac Dysfunction Following Anthracycline Therapy
  The American Journal of Medicine, 2025
• Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial
  Breast Cancer Research and Treatment, 2025
• Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America
  Journal of Cardiac Failure, 2024
• Atorvastatin for Anthracycline-Associated Cardiac Dysfunction
  JAMA, 2023
• Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
  European Journal of Heart Failure, 2020
• Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
  European Journal of Cancer, 2018
• Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure
  JAMA, 2013